Immune system proteins known as monoclonal antibodies are produced in a laboratory. Your body naturally produces antibodies, which assist the immune system in identifying pathogens like viruses and bacteria and marking them for eradication. Monoclonal antibodies, like your body's own antibodies, recognise particular targets.

Monoclonal antibodies (mAbs) are now well-established as targeted treatments for autoimmune and infectious illnesses, cancer, transplant rejection, and a variety of other conditions. However, administering mAbs entails a risk of immunological responses, including the development of antibodies, serum sickness, and acute anaphylaxis. Additionally, mAbs have a wide range of negative side effects that are connected to their particular targets, such as infections, cancer, autoimmune disorders, and adverse events that are specific to certain organs, such cardiotoxicity. A life-threatening cytokine release syndrome that happened in March 2006 during a first-in-human study with the superagonist mAb TGN1412 (which targets CD28) led to a number of recommendations to increase the security of mAb initial human clinical research.

The side effects of monoclonal antibodies can vary from person to person. The ones you might experience and how they make you feel will depend on a variety of elements, including how well you were before treatment, the type of cancer you have, its stage, the monoclonal antibody you are using, and the dosage.

Needle site reactions include:

•           Pain, swelling, soreness, redness, itchiness rash

Flu-like symptoms include:

•           Chills, fatigue, fever, muscle aches and pains, nausea, vomiting, diarrhea

The therapeutic toolbox for treating a range of cancers has been significantly expanded by engineered monoclonal antibodies (MoAbs). These novel chemotherapy regimens are said to have milder adverse effects (AEs) than traditional chemotherapy. There are now 20 MoAbs registered and approved for the treatment of various malignancies. There are 11 distinct targets for these MoAbs. These molecules include five that target the B-lymphocyte antigen CD20, three that target the human epidermal growth factor receptor 2 (HER2 or ErbB2), three that target the epidermal growth factor receptor (EGFR), two that target the vascular endothelial growth factor (VEGF), and one each that targets the epithelial cell adhesion molecule (EpCAM), CD30, CD52, tumour necrosis factor (ligand) superfamily member TNFSF11, also known as RANKL, cytotoxic T lymphocyte-associated protein 4 (CTLA-4), programmed death 1 protein (PD-1) and interleukin-6 (IL-6).

Cancer Clinical Research peer reviewed, open access periodical dedicated to publish the clinical advancements in the cancer research and therapy providing end-to-end solutions, from diagnosis thorough various stages of cancer therapy, pharmaceutical advancements, drug delivery, clinical trials, rehabilitation and care.

Authors can submit their manuscripts as an email attachment to ccr@alliedacademiesscholars.com.

Best Wishes,

Journal Co-ordinator

Journal of Cancer Clinical Research